The Business Times
business-time-50

Lonza in joint venture to develop biotherapeutic products

google-preferred-sourceAdd BT as a preferred source

Ng Ren Jye

Published Wed, Apr 3, 2019 · 09:50 PM

Singapore

SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.

The phased investment of about 90 million euros (S$136.6 million) will be shared equally between the partners over three years.

lonza

TRENDING NOW

Over the past three years, Singapore has overtaken Hong Kong as the top destination for Taiwanese offshore wealth.

Taiwan’s wealthy seeks diversification to Singapore, sparking private banking race: Bloomberg

The onset of El Nino is also seen as a tailwind, as average crude palm oil prices have historically surged during the weather event.

Palm oil stocks set to surge as Indonesia said to be scaling back export overhaul: analysts

Located along Tamarind Road, the five-storey Serenity Park condominium comprises 179 units across 10 blocks.

Serenity Park condo owners lower asking price to S$440 million in second shot at collective sale

Vincent Tan, founder of Berjaya Group, has reduced his holdings in multiple companies within the group.

Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More